Journal of Diabetes Research / 2015 / Article / Tab 2

Research Article

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Table 2

Changes in body weight and glucose metabolic parameters before and after therapies.

Liraglutide (n = 16)P valueIntensive insulin (n = 15)P value
Baseline4 weeksBaseline4 weeks

Body mass index27.3 ± 2.7 26.1 ± 2.3 25.8 ± 2.5 25.1 ± 2.6
 Absolute change−1.3 ± 0.6−1.0 ± 0.8
 % change (%)−4.3 ± 2.4−3.2 ± 2.1
HbA1c (%)8.7 ± 1.08.0 ± 0.88.9 ± 0.97.7 ± 0.8
 Absolute change (%)−0.6 ± 0.4−1.2 ± 0.9
 % change (%)−7.0 ± 4.3−12.8 ± 9.9
Fasting plasma glucose (mg/dL) 149.8 ± 33.3138.0 ± 41.3152.3 ± 30.7108.1 ± 17.9
 Absolute change −11.8 ± 51.5−47.4 ± 36.5
 % change (%)−3.4 ± 34.4−28.2 ± 17.5
Fasting blood CPR (ng/mL) 2.4 ± 1.23.7 ± 1.31.8 ± 0.71.4 ± 0.5
 Absolute change1.3 ± 1.5−0.4 ± 0.4
 % change (%)84.2 ± 92.6−17.2 ± 25.3
C-peptide index 1.65 ± 0.742.84 ± 1.091.26 ± 0.511.28 ± 0.42
 Absolute change1.19 ± 1.010.02 ± 0.27
 % change (%)89.7 ± 65.111.4 ± 34.5
Postprandial plasma glucose (mg/dL) 242.4 ± 62.2166.9 ± 47.0 262.9 ± 67.8134.7 ± 37.6
 Absolute change−75.6 ± 58.6−128.3 ± 59.6
 % change (%)−28.2 ± 19.6−47.0 ± 13.8
Postprandial blood CPR (ng/mL)5.04 ± 3.406.73 ± 2.033.93 ± 2.093.90 ± 1.50
 Absolute change1.45 ± 2.70−0.27 ± 1.45
 % change (%)62.2 ± 80.39.9 ± 37.4
GIR (mg/kg/min)5.51 ± 2.337.64 ± 1.815.46 ± 2.215.86 ± 2.51
 Absolute change 2.13 ± 1.770.40 ± 1.34
 % change (%)63.3 ± 75.211.8 ± 31.5

HbA1c, hemoglobin A1c; CPR, C-peptide radioimmunoreactivity; , and liraglutide-therapy versus intensive insulin-therapy.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.